• Journal of Yeungnam Medical Science
• /
• v.13 no.1
• /
• pp.11-21
• /
• 1996

항암치료에 있어 내성기전은 암세포의 종류에 따라 다양하며 동일세포라도 내성이 생긴 항암제에 따라 그 기능이 다른 것으로 보고되고 있으며 세포종류 및 항암제에 따른 각각의 내성기전을 완전히 알기란 그리 쉬운 일이 아니다. 그러나 임상치료에 있어서 항암제의 적용은 대개 내성 생성이 잘 안되는 즉 교차내성이 적게 일어나는 약제끼리의 선택이 화학요법에 유리하며 재발방지의 지표가 될 수 있으며 내성억제가 가능한 약제의 개발이 중요하다. 또 암에 따른 정확한 내성기전을 잘 밝힘으로서 내성을 방지할 수 있는 target 약제를 함께 병용 개발하는 것이 암의 치료의 지름길이 될 수 있다.

• Tuberculosis and Respiratory Diseases
• /
• v.42 no.3
• /
• pp.302-313
• /
• 1995

Background: Tumor necrosis factor(TNF) showed antitumor cytolytic effects on sensitive tumor cells in numerous in vivo and in vitro studies. But it could not be administered systemically to human because of severe systemic adverse effects at effective concentrations against tumor cells. Many studies showed that a high concentrations of TNF in the local milieu may evoke in vivo TNF-responsive mechanisms sufficient to suppress tumor growth. Recently developed technique of TNF gene transfer to tumor cells using retrovirus vector could be a good candidate for local TNF administration. TNF is also known to synergistically enhance in vitro cytotoxicity of chemotherapeutic drugs targeted to DNA topoisomerase II against TNF-sensitive tumor cell lines. In this study the in vitro chemosensitivity against DNA topoisomerase II targeted chemotherapeutic drugs was evaluated using some respiratory cancer cell lines to which TNF gene had been transferred. Method: NCI-H2058, a human mesothelioma cell line, A549, a human lung adenocarcinoma cell line and WEHI 164 cell line, a murine fibrosarcoma cell line were treated with etoposide and doxorubicin, which are typical topoisomerase II - targeted chemotherapeutic agents, at different concentration. The resultant cytotoxicity was measured by MIT assay. Then the cytotoxicity of the same chemotherapeutic agents was measured after TNF-$\alpha$ gene-transfer and the two results were compared. Results: The cytotoxicity was not increased significantly in WEHI164 cell line and A549 cell line but statistically significant increase was observed in H2058 cell line when TNF-$\alpha$ gene was transferred(p<0.05). Conclusion: These findings show that TNF-$\alpha$ gene transfer to respiratory cancer cell lines results in variable effects on chemosensitivity against topoisomerase II inhibitor among different cell lines in vitro and can be additively cytotoxic in certain selective tumor cell lines.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1993.04a
• /
• pp.131-131
• /
• 1993

위암의 화학요법 성적이 만족스럽지 못하므로 기존의 항암제와 alpha-interferon을 병용사용하므로써 상승적 항암효과가 있는가를 연구하였다. R-25 flask에 위암세포주 SNU-1 및 SNU-16을 배양하면서 항암제 5-FU 혹은 cisplatin에 alpha-interferon 2A(제일제당)를 분자량의 비에 따라 병요처리하였다. 96시간 배양후 cytotoxicity를 Mosman의 방법에 따른 MIT방법으로 분석하였으며, 이를 Chou등의 combination index 분석 program을 처리하였다. 위암세포주 SNU-1에 대하여 5-FU와 alpha-IFN은 상승작용을 보였다. 5-FU의 $IC_{50}$/가 14.25$\mu$M 이었고 IFN처리시는 $IC_{50}$/가 0.02$\mu$M이었으며 combination index(CI)는 모든 용량에서 1이하였다. SNU-16에 대하여도 5-FU와 alpha-IFN의 병용사용은 상승적 작용을 나타내었다. (CI<1.0). cisplatin과 alpha-IFN의 병용시에는 CI가 1이상을 나타내어 상승작용을 증명할 수 없었다.

• Journal of Ginseng Research
• /
• v.27 no.2
• /
• pp.47-51
• /
• 2003

Synergistic anticancer activities of red ginseng acidic polysaccharide (RGAS) showing immunomodulatory activity were evaluated by combined treatment with anticancer agents such as Cyclophosphamide (CY) or 5-Fluorouracil (5-FU) in experimental tumor models. The combined treatment of RGAP (100 mg/kg) and CY (3 mg/kg) exhibited 71% of survival rate in lift span of sarcoma 180-bearing mice, while single treatment of RGAP (100 mg/kg) and CY (3 or 10 mg/kg) exhibited 43, 14 and 43% of survival rates, respectively. In addition, when RGAP (100 mg/kg) was administered in combination with 5-FU (2.5 mg/kg) to sarcoma 180 tumor-bearing mice, higher survival rate was found when compared with RGAP or 5-FU treatment alone. Moreover, tumor weights in LL/2 lung carcinoma-bearing mice treated combined with RGAP (100 mg/kg) and 5-FU (5 or 10 mg/kg) was obviously decreased when compared with 5-FU alone. These results suggest that clinical trials of RGAP as an adjuvant in cancer chemotheraphy can be higly feasible.

• The Science & Technology
• /
• v.28 no.9 s.316
• /
• pp.80-81
• /
• 1995

같은 항암제라도 개인의 신체특성에 따라 효능이 다르게 나타난다. 3차원적으로 조직배양한 표재성 방광암의 암조직과 배양액 내의 포도당 흡수율의 상관관계를 밝혀 항암제 선택의 새로운 지표를 제시, 학계의 관심을 모으고 있는 경희대 비뇨기과 장성구교수가 이달의 과학자로 선정되었다.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1994.04a
• /
• pp.234-234
• /
• 1994

최근 새롭게 조명된 생약에 관한 여러 연구를 통해, 기존의 항암제 보다는 더 효과적이고 인체에는 부작용이 적은 항암제를 개발해내기 위해 국내 자생 생약중 총 103 종류( 95 손 98종 )을 채집하였다. 이들 생약을 암세포주( L1210, P333 D$_1$)와 장상세포주(Vero)을 대상으로 MTT colorimetric assay를 실시하여 항종양성에 대해 알아보았다. 이들 세포주에 대한 $IC_{50}$/ 값으로 세포독성능을 알아보았다. 그리하여 정상세포주에는 적은 세포 독성능을 나타내면서, 암세포주에는 높은 세포 독성능을 나타내는 생약제 6종( BuOH 추출물 2종, MeOH) 추출물 4종 )을 선정하였다. 이중 항암활성능이 가장 높은 미역줄나무(Tripteryrium regelii)를 선택하여 유기용매별로 추출, 그 각각에 대한 세포 독성능이 가장 높게 나타난 2분획을 선택하여 기존에 시판중인 Adriamycin과의 병용 투여시의 세포 독성능의 상승효과를 확인 하였다. 즉 Adriamycin과의 단독 투여보다 복합 투여시에 암세포주에 대한 세포 독성능이 높아졌고, 정상세포주에 대한 독성이 감소되는 효과가 나타났다. 또한 in vitro 에서는 세포 독성능이 다소 적더라도 in vivo에서 면역학적 활성이 기대되는 생약제 3종을 선정하여 항암성분의 분리 및 정제를 하여 항암성에 대하여 알아보았다.

• 대한임상약리학회:학술대회논문집
• /
• 1993.12a
• /
• pp.22-22
• /
• 1993

• Bioindustry News
• /
• v.13 no.4
• /
• pp.22-30
• /
• 2000

• Analytical Science and Technology
• /
• v.23 no.6
• /
• pp.579-586
• /
• 2010

Commercially widely used antitumor agents such as hydroxy urea, 6-mercaptopurine monohydrate, cytosine arabinoside, cyclophosphamide monohydrate and uracil were reacted with 3-(triethoxysilyl)propyl isocyanate and the product hydrolyzed to give silica nanoparticles bound antitumor agents ranging from 10 nm to micron-sized aggregates. The silyl isocyanate derivative was also reacted neat with water to give hybrid organicsilicananoparticles containing $-CH_2-CH_2-CH_2-NH-COOH$ or the corresponding decarboxylated propylamine groups depending on solvent and temperature employed. In vitro tests these functionalized silica nanoparticles were effective in the treatment of malignant tumor cells but had little or no effect on normal cells. Malignant human lung, ovarian, melanoma, CNS(Central nervous system) and colon tumor cells were used in this research. The use of silica as a carrier medium in the present research serves as a model material due to its ready functionalization via silation. The proof of concept established by the results suggests that the technique may be applied to other, more biocompatible carrier nanoparticles.

• Polymer(Korea)
• /
• v.35 no.2
• /
• pp.119-123
• /
• 2011

To develop hyaluronic acid (HA)-based anticancer agent carrier, hyaluronic acid was chemically modified with the hydrophobic group of deoxycholic acid(DA). The physicochemical properties of the deoxycholic acid-conjugated HA (HADA) were investigated by using $^1H$ NMR, FTIR spectrophotometer and TEM. Paclitaxel (Tx)-loaded HADA nanoparticles were prepared by a dialysis method. The loading efficiency of drug and drug contents of Tx-loaded HADA nanoparticles (HADA-Tx) were measured by HPLC. The anticancer activity of HADA-Tx was investigated by its cytotoxicity against KB cell in vitro. The HADA-Tx was shown to have the superior potential for the anticancer drug delivery.